马来西亚心脏病患者中因他类药物引起的勃起功能障碍的遗传预测
Naam Bahjat Ahmed Adeeb1,2, Hadeer Akram Al-Ani3, Nur Aizati Athirah Daud1,4
1Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kota Bharu 16150, Kelantan, Malaysia.
International journal of molecular sciences
|September 13, 2025
概括
静止剂的使用可能会增加男性的勃起功能障碍 (ED) 风险,特别是影响NR2F2-AS1和NOS3基因. 阿托瓦斯塔丁表现出多种效应,其中CYP17A1受影响最大.
科学领域:
- 心血管遗传学 心血管遗传学
- 药物基因组学 药物基因组学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 勃起功能障碍 (ED) 在患有心血管疾病和糖尿病的患者中很普遍.
- 新出现的证据表明,他类药物治疗可能会增加患ED的风险.
- 遗传倾向越来越多地被认为是导致ED的因素.
研究的目的:
- 研究在接受他类药物治疗的马来西亚心脏病患者中特定基因多态度和ED之间的关联.
- 通过基因分析,探索他类药物,特别是阿托瓦斯塔丁对ED风险的影响.
- 为了识别使用他类药物的男性影响ED的新型遗传因素.
主要方法:
- 一项涉及246名心脏病患者的横截面遗传研究.
- 患者根据他类药物的使用,ED状态和糖尿病被分为四组.
- 对六个候选基因 (CYP19A1,CYP17A1,SIM1,TP53,NR2F2,NOS3) 的分析及其与ED相关的多态性.
主要成果:
- 立方体治疗对ED产生了负面影响,显著影响NR2F2-AS1和NOS3基因变异.
- 阿托瓦斯塔丁在所有研究的基因中表现出差异性影响,对CYP17A1的影响最为明显,对CYP19A1的影响最少.
- 在使用他类药物的背景下,特定的基因多态性被确定为ED的潜在贡献者.
结论:
- 这项研究突出了影响马来西亚男性使用他类药物的ED的显著遗传因素.
- 研究结果表明,NR2F2-AS1和NOS3是与ED有关的关键基因,受到他类药物治疗的影响.
- 阿托瓦斯塔丁对各种基因的差异性影响为ED管理提供了个性化医学方法的见解.
相关概念视频
Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Human Genetics
1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Coronary Artery Disease IV: Preventive Measures
563
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
563

